CEPHALON/CHIRON COLLABORATION FOR NEUROLOGICALS IGF-1
Executive Summary
CEPHALON/CHIRON COLLABORATION FOR NEUROLOGICALS IGF-1, human SOD, bFGF and Cardioxane has as its initial focus insulin-like growth factor for the treatment of amyotrophic lateral sclerosis (Lou Gehrig's disease) and additional neurological disorders, the companies jointly announced Jan. 11. The R&D and marketing collaboration also will develop Chiron's human superoxide dismutase (hSOD), basic fibroblast growth factor (bFGF) and Cardioxane, an antioxidant.